Skip to main content

Table 1 Clinicopathological implication of Ki67-p53 combination status in surgically resected hormone receptor-positive breast cancers

From: A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

Variables

Cases

 

Ki67-p53 combination status

 

Total

Low Ki67 LIand Negative p53

High Ki67 LI and/or Positive p53

P- value

 

(n=150)

(n=88)

(n=62)

 

Age

    

   50

71

40

31

 

   >50

79

48

31

0.58

Tumor size

    

   <5.0 cm

128

78

50

 

   5.0 cm

19

8

11

0.12

   Unknown

3

2

1

 

Lymph node metastasis

   (−)

84

52

32

 

   (+)

63

34

29

0.33

   Unknown

3

2

1

 

Stage

    

   I or II

129

78

51

 

   III

17

7

10

0.13

   Unknown

4

3

1

 

Nuclear grade

    

   1, 2

115

76

39

 

   3

35

12

23

0.0008

HER2 status

    

   Negative

142

88

54

 

   Positive

8

0

8

0.0006

Basal phenotype marker (CK5/6, CK14, EGFR)

   Negative

140

87

53

 

   Positive

10

1

9

0.0016

FOXA1

    

   Negative

20

14

6

 

   Positive

127

72

55

0.38

   NE

3

2

1

 

GATA3

    

   Negative

30

18

12

 

   Positive

120

70

50

0.99

P-cadherin

    

   Low

94

62

32

 

   High

56

26

30

0.0019

Chemotherapy

    

   No

98

59

39

0.59

   Yes

52

29

23

 
  1. Abbreviation: LI labeling index, NE not evaluable.